Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lung Neoplasms 29Ovarian Neoplasms 27Fallopian Tube Neoplasms 24Carcinoma, Non-Small-Cell Lung 23Colorectal Neoplasms 16Melanoma 12Carcinoma, Renal Cell 12Carcinoma, Hepatocellular 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 11Glioblastoma 11Breast Neoplasms 11Triple Negative Breast Neoplasms 10Urinary Bladder Neoplasms 8Prostatic Neoplasms 8Neoplasm Metastasis 8Uterine Cervical Neoplasms 7Brenner Tumor 7Mycosis Fungoides 6Colonic Neoplasms 6Brain Neoplasms 6Rectal Neoplasms 5Multiple Myeloma 5Lymphoma, T-Cell, Cutaneous 5Endometrial Neoplasms 5Sezary Syndrome 4Sarcoma 4Neoplasms 4Nasopharyngeal Carcinoma 4Lymphoma, Large B-Cell, Diffuse 4

Interventions

Specimen Handling 2talazoparib 1Taxes 1Paclitaxel 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Cyclophosphamide 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Adenocarcinoma × Immunoglobulin G × Clear all
NCT00433511 2026-05-29

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
4,994 enrolled 11 charts
Breast

Breast Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡